Novartis, Amgen and the Banner Alzheimer’s Institute announced they are halting two pivotal Phase II/III clinical trials in the Alzheimer’s Prevention Initiative Generation Program.
Takeda Pharmaceutical Co. Ltd. will discontinue a late-stage study testing the company’s experimental treatment for amyloidosis, which did not meet the first of two main goals.
Unfortunately, 2018 marked yet another bad year for Alzheimer’s disease drug development, with at least half-a-dozen major clinical drug trial failures.
Aggressively lowering blood pressure significantly reduced the risk of mild cognitive impairment and dementia among hypertension patients in a large government-backed clinical trial, U.S. researchers said.
Lilly has closed off another avenue for solanezumab, its once-promising experimental therapy for Alzheimer’s disease, after scrapping another Phase III study.
Anavex Life Sciences Corp. (NASDAQ:AVXL) may have just emerged as a significant player in the Alzheimer’s drug market. The clinical-stage biotech company specializes in the development of treatments for currently incurable diseases. It has stumbled upon AVANEX 3-71 which is a drug candidate that may have significant potential for reduction of synaptic loss, amyloid, and […]